(A) Dose-response curves for N::TVA;Cdkn2alox/lox;Atrxlox/lox;Ptenlox/lox mouse astrocytes (left panel) and tumor cells (right panel) expressing PDGFA, Cre, and IDH1R132H treated with olaparib and TMZ.
(B) Dose-response curves for N::TVA;Cdkn2alox/lox;Atrxlox/lox;Ptenlox/lox mouse astrocytes and tumor cells expressing PDGFA, Cre, and WT IDH1 treated with olaparib and TMZ.
(C) Quantification of cell viability in mouse astrocytes expressing wild-type or mutant IDH1 treated with olaparib alone (25 μM), TMZ alone (10 μM, 50 μM; inset), and olaparib in combination with TMZ.
(D) Quantification of cell viability in wild-type and mutant IDH1 glioma-derived cells treated with olaparib alone (25 μM), TMZ alone (10 μM, 50 μM; inset), and in combination with TMZ.
Data are expressed as the mean ± SEM with three replicates. Significance is denoted: *p < 0.05, **p < 0.01, ***p < 0.001. lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. J. Cell Biol. 185, 797–810.